Gene Therapy for Chronic Granulomatous Disease — CGD

Granulomatous Disease, Chronic Clinical Trial

Official title:
Phase I/II Gene Therapy Study for X-Linked Chronic Granulomatous Disease

Status Active, not recruiting

Clinical Trial Summary

The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan)patients with chronic granulomatous disease (CGD). Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00564759
Study type	Interventional
Source	Johann Wolfgang Goethe University Hospitals
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	January 2004
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02231996` - Chronic Granulomatous Disease Study in China	N/A
Completed	`NCT00010361` - Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders	N/A
Enrolling by invitation	`NCT02082353` - Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
Recruiting	`NCT00001405` - Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
Completed	`NCT00033982` - Posaconazole to Treat Invasive Fungal Infections	Phase 3